Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThis updates the ClinicalTrials.gov page’s visible revision/version label from v3.5.2 to v3.5.3 without changing any underlying study details.SummaryDifference0.1%

- Check23 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No visible changes to study content or page functionality.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page footer now shows Revision: v3.4.3, replacing the previous Revision: v3.4.2.SummaryDifference0.1%

- Check88 days agoChange DetectedThe footer revision tag was updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check95 days agoChange DetectedRevision: v3.4.1 replaces the previous v3.4.0 on the page.SummaryDifference0.1%

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.